Phase 3 Readout

AMLX: Phase 3 Topline: A Phase 3 Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy a

Name: Phase 3 Topline: A Phase 3 Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy a
Start: 2027-02-01
End: 2027-02-01

February 1, 2027 · post-bariatric. BioSniper AI can trace the company-impact path without requiring you to write the research question.

Event date: February 1, 2027
Company: Amylyx Pharmaceuticals, Inc. (AMLX)
Drug: post-bariatric

BioSniper AIPage evidence connected

Prepared research question

What could this event change, and which evidence should be watched next?

Run cited research

Traceable citations · Unknowns marked

Phase 3 Readout~month

Phase 3 Topline: A Phase 3 Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy a

February 1, 2027

AMLX overview →

Company: Amylyx Pharmaceuticals, Inc. (AMLX)
Drug: post-bariatric
Indication: Post Bariatric Hypoglycemia